In the context of cancer, EGF can become problematic when it leads to the overexpression or mutation of EGFR. When EGFR is overexpressed, it can result in the continuous activation of signaling pathways that promote cell proliferation and survival, leading to uncontrolled tumor growth. Mutations in EGFR are particularly common in certain types of cancers, including non-small cell lung cancer (NSCLC), glioblastomas, and colorectal cancers.
